Member Info for Nextlink

NSCI hold approximately 4.7% of PDS.
Today following further good news from PDS it's share price is up.
However it is the volume of PDS shares traded so far, which is of interest.
There are approximately 30 million PDS shares in issue and we are approaching
10 million shares traded with almost 5 hours before close of trade.
So almost a third traded.
My thought is that an institution is taking a major stake - it's brokers
are selling large quantities, whilst also buying.
In order to fill the order, at as low a price as possible.
If I am right the share price will really take off as we reach
the end of trading in New York.

I should have viewed the Video

Hemotruth which planet are you on ?
Here on Earth a month is around 30 days, unlike your 10 days.

Yes a free 16% holding and some cash as stated below -
16% equity stake in partial settlement of fees
It is astounding the progress nsci are making in increasing their portfolio, with so many
exciting companies.
PDS looking to be close to major news, possibly before the end of this year.
We both know this company looks to be the hidden diamond, overlooked and unloved
in these difficult markets

Whenever PDS update the US market, it is usually the following day NSCI announce it.
Not only was the update before close of trading in London it was soon after it was published
in New York.

Excellent news from PDSB regarding their universal flu vaccine
today announced an upcoming poster presentation at the 41st annual meeting of the American Society of Virology meeting.
All animals vaccinated with PDS0202 survived a lethal challenge with the H1N1 pandemic strain of influenza, compared to a ~40% survival rate in animals vaccinated with COBRA antigens only and a 0% survival rate in untreated animals.

Thanks for your update

As of 8th June he held 27.95% .
If it was him those two buys add just under another 1.715%.
So he is getting close to the 30% ceiling.
Cannot see him bidding for the Company so he has to stop buying.

In Summary - assuming he is the buyer and those were two separate buys.
Suggests news imminent.

Two days of approximately four times average volume and heavy fall in sp
Volume in excess of 1.2 million shares traded each day.

Today announcement of fast track for PDS0101 in combination with Keytruda
https://newsfilter.io/articles/pds-biotechnology-granted-fda-fast-track-designation-for-lead-candidate-pds0101-0f6d394fc139b59742198fe46f232192
Already almost 14 million shares traded in the first hour and a half. SP recovering.

As I understand it the trial consists of patients at stage 5 cancer of the head & neck with an average four month
life expectancy. Latest update on 26th May shows 89% of patients alive at median 9 months, does not look bad to me.
I suspect with 19 patients it is challenging statistically, hence the expansion of the trial to the UK.
The larger the cohort the more accurately you can assess the benefit or non benefit of the treatment.

Having followed PDSB for a while it seems obvious to me the market for this small stock (for US market) is rigged.
We may see one or more institutions have sold heavily.
I have a theory - which coud be wishful thinking on my part that this is part of Merk's opening move, unsettling traders, small investors by exploiting a small difference since the last update relating to patients on the lowest dose.
That whilst we see heavy selling - Merk are already accumulating stock at very low prices.

Versamune-002 trial is being extended to UK
https://newsfilter.io/a/9d5ecc06bf322e3d6d743878924cc00f

Good news from PDSB to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022 in Chicago

https://www.sec.gov/Archives/edgar/data/1472091/000114036122020836/brhc10038208_ex99-1.htm

April 13th & 14th Excel London activity

https://www.eges.gg/agenda

On the ball as usual.
Excellent spot and shows Sage may be approaching a public
listing next year.

ProAxsis Ltd (100% owned subsidiary)
Glycotest (64% holding)
PDS Biotechnology (NASDAQ Listed, 4.7% holding)
EMV Capital (100% subsidiary, corporate finance arm)
As shareholders in NSCI we hold the above stakes.

Below open to debate - you say 2.25% stake in SageTech
Several direct investments were made by NetScientific in the portfolio companies as part of the capital light investment model, and to enable the syndication of further funds by EMVC
Pointgrab (23% stake)
SageTech (23.8% stake)
Sofant (25.7% stake)

I would say fair value for £23 million market cap and some cash

I have found the below so looks like my mistake.

Fingers crossed all goes well.

https://connectonline.asic.gov.au/RegistrySearch/faces/landing/SearchRegisters.jspx?_afrLoop=3003402451040482&_afrWindowMode=0&_adf.ctrl-state=od3qhs8j2_4

We all recall the fiasco that was Daniel Mark Harrison and Monkey Capital.

I thought I would search Australia's equivalent of Companies House
I searched by name
https://sitesearch.asic.gov.au/s/search.html?query=GUINEVERE+CAPITAL&collection=asic&profile=asic

Then by Company Number located on this site https://opencorporates.com/companies/au/610943774

https://sitesearch.asic.gov.au/s/search.html?query=610943774&collection=asic&profile=asic

In each case I found nothing.
I also note Guinevere Capital's website is very basic - not that that is in itself indicative of anything .

Maybe I have made a basic error and perhaps someone can show we where I went wrong.

No not on Options - unless exercised.

You have been told they cannot be exercised until October 2022 and also the sp has to be
above 37 pence for 30 days in a row.

So they cannot collect any Dividend paid before October 2022 in any circumstance on
those Options.

Regarding Vortex.

Looking at 29th September Interim s they list an owned and an advised portfolio.
PDS for example is in the owned portfolio indicating we own 4.7%.

Vortex is in the advised portfolio listed at 96%

NSCI took over EMV , acquiring it's Portfolio, described below.

EMVC Evergreen EIS Fund is a discretionary portfolio which will make investments into EIS Qualifying Companies in technologies driving the advancement of British industrial high-tech and its applications; including robotics, artificial intelligence, machine vision, electronics, IoT and materials science. EMV Capital is exclusive adviser to the fund which is managed by Sapphire Capital Partners.

Is it the case EMV , now NSCI held 20% directly.
The additional 76% being clients of EMV, on which we are receiving fee income.

I would not make any stock recommendation.
I am no youngster and made some poor investment decisions over the years.
Also I am not authorised by the FCA to give investment advice.

Looked at SYME back in October 2010 when it was 0.48 pence a share
and disliked what I saw.
I thought it was a scam then, all the news since then has confirmed
that belief.

I hope for your sake that I am wrong and cursing my missing out on a fantastic investment.

Lets see who is right over the next few months.